The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
 
Rong Duan
No Relationships to Disclose
 
Yixun Liu
No Relationships to Disclose
 
Xuechun Hu
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche China; Shanghai Junshi Biosciences
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Zhi Liu
No Relationships to Disclose
 
Ping Xiang
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Li Zhou
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Yu Jie Li
Employment - Lee's Pharmaceutical
 
Rachel Ng
Employment - Lee's Pharmaceutical
 
Xiang Rong Dai
Employment - Lee's Pharmaceutical
 
Benjamin Xiaoyi Li
Employment - Lee's Pharmaceutical
 
Zhihong Chi
No Relationships to Disclose
 
Jun Xiao
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Bixia Tang
No Relationships to Disclose